Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
RPRX Quote, Financials, Valuation and Earnings
Last price:
$39.26
Seasonality move
:
3.43%
Day range:
$39.24 - $39.50
52-week range:
$25.02 - $41.24
Dividend yield:
2.24%
P/E ratio:
22.45x
P/S ratio:
9.56x
P/B ratio:
2.61x
Volume:
1.1M
Avg. volume:
4.3M
1-year change:
55.57%
Market cap:
$16.8B
Revenue:
$2.3B
EPS (TTM):
$1.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$763.5M | $1.04 | 41.41% | 180.59% | $46.32 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
DNLI
Denali Therapeutics, Inc.
|
$1M | -$0.76 | 559.6% | -13.28% | $32.21 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 31.31% | 54.16% | $1,093.22 |
|
ZBIO
Zenas BioPharma, Inc.
|
$10M | -$0.85 | 1166.67% | -5.46% | $49.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$39.25 | $46.32 | $16.8B | 22.45x | $0.22 | 2.24% | 9.56x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.79 | $491.92 | $52.9B | 1,666.49x | $0.00 | 0% | 16.44x |
|
AMGN
Amgen, Inc.
|
$333.89 | $325.88 | $179.8B | 25.81x | $2.38 | 2.85% | 5.04x |
|
DNLI
Denali Therapeutics, Inc.
|
$16.99 | $32.21 | $2.7B | -- | $0.00 | 0% | 6.62x |
|
LLY
Eli Lilly & Co.
|
$1,076.98 | $1,093.22 | $963.9B | 53.26x | $1.50 | 0.56% | 16.52x |
|
ZBIO
Zenas BioPharma, Inc.
|
$43.17 | $49.00 | $1.8B | -- | $0.00 | 0% | 120.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
58.29% | 0.918 | 49.28% | 3.47x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
ZBIO
Zenas BioPharma, Inc.
|
0.41% | 0.444 | 0.09% | 5.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$608M | $427.2M | 7.29% | 13.15% | 70.11% | -$258.4M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
ZBIO
Zenas BioPharma, Inc.
|
-$11K | -$47.6M | -67.98% | -68.2% | -373.3% | -$41.1M |
Royalty Pharma Plc vs. Competitors
-
Which has Higher Returns RPRX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 20.1%. Royalty Pharma Plc's return on equity of 13.15% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About RPRX or ALNY?
Royalty Pharma Plc has a consensus price target of $46.32, signalling upside risk potential of 18.01%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 23.38%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Royalty Pharma Plc.
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is RPRX or ALNY More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock RPRX or ALNY?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.24%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or ALNY?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Royalty Pharma Plc's net income of $444.2M is higher than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.45x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,666.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.56x versus 16.44x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.56x 22.45x $609.3M $444.2M ALNYAlnylam Pharmaceuticals, Inc.16.44x 1,666.49x $1.2B $251.1M
-
Which has Higher Returns RPRX or AMGN?
Amgen, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 33.55%. Royalty Pharma Plc's return on equity of 13.15% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About RPRX or AMGN?
Royalty Pharma Plc has a consensus price target of $46.32, signalling upside risk potential of 18.01%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -1.69%. Given that Royalty Pharma Plc has higher upside potential than Amgen, Inc., analysts believe Royalty Pharma Plc is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 AMGNAmgen, Inc.10 15 2 -
Is RPRX or AMGN More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock RPRX or AMGN?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.24%. Amgen, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $2.38 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.
-
Which has Better Financial Ratios RPRX or AMGN?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Royalty Pharma Plc's net income of $444.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.45x while Amgen, Inc.'s PE ratio is 25.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.56x versus 5.04x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.56x 22.45x $609.3M $444.2M AMGNAmgen, Inc.5.04x 25.81x $9.6B $3.2B
-
Which has Higher Returns RPRX or DNLI?
Denali Therapeutics, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of --. Royalty Pharma Plc's return on equity of 13.15% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About RPRX or DNLI?
Royalty Pharma Plc has a consensus price target of $46.32, signalling upside risk potential of 18.01%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.21 which suggests that it could grow by 89.61%. Given that Denali Therapeutics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Denali Therapeutics, Inc. is more attractive than Royalty Pharma Plc.
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 DNLIDenali Therapeutics, Inc.17 0 0 -
Is RPRX or DNLI More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.
-
Which is a Better Dividend Stock RPRX or DNLI?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.24%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or DNLI?
Royalty Pharma Plc quarterly revenues are $609.3M, which are larger than Denali Therapeutics, Inc. quarterly revenues of --. Royalty Pharma Plc's net income of $444.2M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.45x while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.56x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.56x 22.45x $609.3M $444.2M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns RPRX or LLY?
Eli Lilly & Co. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 31.72%. Royalty Pharma Plc's return on equity of 13.15% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About RPRX or LLY?
Royalty Pharma Plc has a consensus price target of $46.32, signalling upside risk potential of 18.01%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Royalty Pharma Plc has higher upside potential than Eli Lilly & Co., analysts believe Royalty Pharma Plc is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 LLYEli Lilly & Co.18 7 0 -
Is RPRX or LLY More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock RPRX or LLY?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.24%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or LLY?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Royalty Pharma Plc's net income of $444.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.45x while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.56x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.56x 22.45x $609.3M $444.2M LLYEli Lilly & Co.16.52x 53.26x $17.6B $5.6B
-
Which has Higher Returns RPRX or ZBIO?
Zenas BioPharma, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of -335.73%. Royalty Pharma Plc's return on equity of 13.15% beat Zenas BioPharma, Inc.'s return on equity of -68.2%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B ZBIOZenas BioPharma, Inc.-- -$1.22 $197.2M -
What do Analysts Say About RPRX or ZBIO?
Royalty Pharma Plc has a consensus price target of $46.32, signalling upside risk potential of 18.01%. On the other hand Zenas BioPharma, Inc. has an analysts' consensus of $49.00 which suggests that it could grow by 13.51%. Given that Royalty Pharma Plc has higher upside potential than Zenas BioPharma, Inc., analysts believe Royalty Pharma Plc is more attractive than Zenas BioPharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 ZBIOZenas BioPharma, Inc.7 0 0 -
Is RPRX or ZBIO More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Zenas BioPharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RPRX or ZBIO?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.24%. Zenas BioPharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Zenas BioPharma, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or ZBIO?
Royalty Pharma Plc quarterly revenues are $609.3M, which are larger than Zenas BioPharma, Inc. quarterly revenues of --. Royalty Pharma Plc's net income of $444.2M is higher than Zenas BioPharma, Inc.'s net income of -$51.5M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.45x while Zenas BioPharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.56x versus 120.60x for Zenas BioPharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.56x 22.45x $609.3M $444.2M ZBIOZenas BioPharma, Inc.120.60x -- -- -$51.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
